Datasheet

EBI3 Antibody
CATALOG NUMBER: 4977

Availability: In stock

$0.00
Product Price Options

* Required Fields

$0.00
Specifications
Properties
Additional Info
Background

Specifications

SPECIES REACTIVITY:Human, Mouse, Rat
TESTED APPLICATIONS:ELISA, IF, IHC-P, WB
APPLICATIONS:EBI3 antibody can be used for the detection of EBI3 by Western blot at 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μg/mL. For immunofluorescence start at 20 μg/mL.
USER NOTE:Optimal dilutions for each application to be determined by the researcher.
POSITIVE CONTROL:1) Cat. No. 1466 - Rat Spleen Tissue Lysate
 2) Cat. No. 10-901 - Human Spleen Tissue Slide
IMMUNOGEN:EBI3 antibody was raised against a 16 amino acid synthetic peptide from near the center of human EBI3.

The immunogen is located within amino acids 150 - 200 of EBI3.
HOST SPECIES:Rabbit

Properties

PURIFICATION:EBI3 Antibody is affinity chromatography purified via peptide column.
PHYSICAL STATE:Liquid
BUFFER:EBI3 Antibody is supplied in PBS containing 0.02% sodium azide.
CONCENTRATION:1 mg/mL
STORAGE CONDITIONS:EBI3 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
CLONALITY:Polyclonal
ISOTYPE:IgG
CONJUGATE:Unconjugated

Additional Info

ALTERNATE NAMES:EBI3 Antibody: IL27B, IL-27B, IL27B, Interleukin-27 subunit beta, Epstein-Barr virus-induced gene 3 protein, IL-27 subunit beta
ACCESSION NO.:NP_005746
PROTEIN GI NO.:14577917
OFFICIAL SYMBOL:EBI3
GENE ID:10148

Background

BACKGROUND:EBI3 Antibody: EBI3 is a subunit in two distinct heterodimeric cytokines: interleukin-27 (IL-27) and IL-35. Like interleukin-23 (IL-23), IL-27 is a recently discovered member of the IL-6/IL-12 family of proinflammatory and immunoregulatory cytokines. It exists as a heterodimer composed of the p40-related protein EBI3 and an IL-12 p35-related protein termed p28. IL-27 is produced after activation by antigen-presenting cells and induces proliferation of naïve but not memory CD4+ T-cells. It acts by binding to its receptor WSX-1 (also known as TCCR) and gp130 which results in the activation of a Jak/STAT signaling cascade, suggesting the IL-27 is involved in the regulation of immune processes. It has been suggested that IL-27 can also be used as a therapeutic agent against cancer as it can also induce tumor-specific anti-tumor activity mediated through CD8+ T-cells, IFN-gamma, and T-bet. IL-35 is composed of EBI3 and the p35 subunit of IL-12 and has been reported to have therapeutic effects against collagen-induced arthritis by expanding the population of regulatory T cells and suppressing Th17 cells. At least two isoform of EBI3 are known to exist.
REFERENCES: 1) Pfanz S, Timans JC, Cheung J et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naïve CD4(+) T cells. Immunity2002; 16:779-90.
2) Devergne O, Birkenbach M, and Kieff E. Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin form a novel heterodimeric hematopoietin. Proc. Natl. Acad. Sci. USA1997; 94:12041-6.
3) Niedbala W, Wei X, Cai B, et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expression of regulatory T cells and suppression of Th17 cells. Eur. J. Immunol.2007; 3021-29.
4) Pfanz S, Hibbert L, Mattson J, et al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J. Immunol.2004; 172:2225-31.

For Research Use Only